Free Trial
NASDAQ:HOTH

Hoth Therapeutics (HOTH) Stock Price, News & Analysis

Hoth Therapeutics logo
$1.20 +0.01 (+0.42%)
Closing price 07/3/2025 03:36 PM Eastern
Extended Trading
$1.20 0.00 (0.00%)
As of 07/3/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Hoth Therapeutics Stock (NASDAQ:HOTH)

Key Stats

Today's Range
$1.18
$1.23
50-Day Range
$0.84
$1.53
52-Week Range
$0.58
$3.80
Volume
132,991 shs
Average Volume
3.73 million shs
Market Capitalization
$15.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Hoth Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

HOTH MarketRank™: 

Hoth Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 780th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hoth Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Hoth Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Hoth Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Hoth Therapeutics are expected to grow in the coming year, from ($1.36) to ($0.97) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hoth Therapeutics is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hoth Therapeutics is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Hoth Therapeutics has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Hoth Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.75% of the float of Hoth Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Hoth Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hoth Therapeutics has recently increased by 1,946.26%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Hoth Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Hoth Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.75% of the float of Hoth Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Hoth Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hoth Therapeutics has recently increased by 1,946.26%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Hoth Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 6 people have searched for HOTH on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hoth Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.92% of the stock of Hoth Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 7.08% of the stock of Hoth Therapeutics is held by institutions.

  • Read more about Hoth Therapeutics' insider trading history.
Receive HOTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOTH Stock News Headlines

Hoth Therapeutics (NASDAQ:HOTH) Upgraded to Hold at Wall Street Zen
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
HOTH THERAPEUTICS INC - FinanzNachrichten.de
See More Headlines

HOTH Stock Analysis - Frequently Asked Questions

Hoth Therapeutics' stock was trading at $0.7481 at the beginning of the year. Since then, HOTH stock has increased by 61.1% and is now trading at $1.2050.

Hoth Therapeutics, Inc. (NASDAQ:HOTH) issued its quarterly earnings results on Monday, May, 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.07.

Shares of Hoth Therapeutics reverse split before market open on Wednesday, October 26th 2022.The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Hoth Therapeutics (HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hoth Therapeutics investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Meta Platforms (META), NVIDIA (NVDA) and Zomedica (ZOM).

Company Calendar

Last Earnings
5/12/2025
Today
7/06/2025
Next Earnings (Estimated)
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HOTH
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$5.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+232.0%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.19 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.86 per share
Price / Book
1.40

Miscellaneous

Free Float
12,295,000
Market Cap
$15.92 million
Optionable
Not Optionable
Beta
0.67
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:HOTH) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners